{"id":94,"date":"2018-06-19T12:00:46","date_gmt":"2018-06-19T16:00:46","guid":{"rendered":"https:\/\/wordpress-dev.med.unc.edu\/millerlab\/?page_id=94"},"modified":"2018-12-27T11:06:03","modified_gmt":"2018-12-27T16:06:03","slug":"crm-publications","status":"publish","type":"page","link":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/publications\/crm-publications\/","title":{"rendered":"CRM Publications"},"content":{"rendered":"
\n

CRM NCBI Bibliography<\/a><\/h2>\n

2018<\/h3>\n
    \n
  1. Koehler JW*, Miller AD*, Miller CR<\/strong>*, Porter B*, Aldape K, Beck J, Brat D, Cornax I, Corps K, Frank C, Giannini C, Horbinski C, Huse JT, O\u2019Sullivan MG, Rissi DR, Simpson RM, Woolard K, Shih JH, Mazcko C, Gilbert MR, LeBlanc AK. A revised diagnostic classification of canine glioma: Towards validation of the canine glioma patient as a naturally occurring preclinical model for human glioma.\u00a0 Journal of Neuropathology and Experimental Neurology.\u00a0 77(11):1039-1054 Nov 2018.\u00a0 PMID: 30239918<\/a>\u00a0 PMCID: PMC6181180<\/a>\u00a0 *Contributed equally<\/li>\n
  2. Van Swearingen AED, Siegel MB, Deal AM, Sambade MJ, Hoyle A, Hayes DN, Jo H, Little P, Dees EC, Muss H, Jolly T, Zagar TM, Patel N, Miller CR<\/strong>, Parker JS, Smith JK, Fisher J, Shah N, Nabell L, Nanda R, Dillon P, Puhalla S, Abramson V, Carey LA, Anders CK.\u00a0 LCCC 1025: A phase II study of everolimus, trastuzumab and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.\u00a0 Breast Cancer Research and Treatment.\u00a0 171(3):637-648 Oct 2018.\u00a0 PMID: 29938395<\/a><\/li>\n
  3. Kesarwani P, Prabhu A, Kant S, Kumar P, Graham SF, Buelow K, Wilson G, Miller CR<\/strong>, Chinnaiyan P. Tryptophan metabolism contributes to radiation-induced immune checkpoint reactivation in glioblastoma. Clinical Cancer Research.\u00a0 24(15):3632-3643\u00a0Aug 2018.\u00a0 PMID: 29691296<\/a><\/li>\n
  4. Okolie O, Irvin DM<\/strong>, Bago JR, Sheets K, Satterlee A, Carey-Ewend AG, Lettry V, Dimitru R, Elton S, Ewend MG, Miller CR<\/strong>, Hingtgen SD.\u00a0 Intra-cavity stem cell therapy inhibits tumor progression in a novel murine model of medulloblastoma surgical resection.\u00a0 PLoS One.\u00a0 13(7):e0198596 Jul 2018.\u00a0 PMID: 29990322<\/a>\u00a0PMCID: PMC6038981<\/a><\/li>\n
  5. McNeill RS<\/strong>, Stroobant EE<\/strong>, Smithberger E<\/strong>, Canoutas DA<\/strong>, Butler MK<\/strong>, Shelton AK<\/strong>, Patel SD<\/strong>, Limas JC, Skinner KR<\/strong>, Bash RE<\/strong>, Schmid RS<\/strong>, Miller CR<\/strong>.\u00a0 PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition.\u00a0 PLoS One.\u00a0 13(7):e0200014 Jul 2018.\u00a0 PMID: 29975751<\/a>\u00a0 PMCID: PMC6033446<\/a><\/li>\n
  6. Galanis E, Anderson SK, Miller CR<\/strong>, Sarkaria JN, Jaeckle K, Buckner JC, Ligon KL, Ballman KV, Moore DF Jr, Nebozhyn M, Loboda A, Schiff D, Ahluwalia MS, Lee EQ, Gerstner ER, Lesser GJ, Prados M, Grossman SA, Cerhan J, Giannini C, Wen PY, Alliance for Clinical Trials in Oncology and Adult Brain Tumor Consortium (ABTC). Phase I\/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: Results of Alliance N0874\/ABTC 02.\u00a0 Neuro-oncology.\u00a0 20(4):546-556 Mar 2018.\u00a0 PMID: 29016887<\/a>\u00a0 PMCID:\u00a0 PMC5909661<\/a><\/li>\n
  7. Danussi C, Bose P, Parthasarathy PT, Silberman PC, Van Arnam JS, Vitucci M, Tang OY, Heguy A, Chan TA, Riggins GJ, Sulman EP, Lang F, Creighton CJ, Deneen B, Miller CR<\/strong>, Picketts DJ, Kannan K, Huse JT. Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling.\u00a0 Nature Communications.\u00a0 9(1):1057 Mar 2018.\u00a0 PMID: 29535300<\/a> \u00a0PMCID:\u00a0 PMC5849741<\/a><\/li>\n
  8. Graham-Gurysh EG, Moore KM, Satterlee AB, Sheets KT, Lin FC, Bachelder EM, Miller CR<\/strong>, Hingtgen S, Ainslie KM. Sustained delivery of doxorubicin via acetalated dextran scaffold prevents glioblastoma recurrence after surgical resection.\u00a0 Molecular Pharmaceutics.\u00a0 15(3):1309-1318 Mar\u00a0 PMID: 29342360<\/a>\u00a0 PMCID:\u00a0 PMC5999333<\/a><\/li>\n
  9. Allott EH, Geradts J, Cohen SM, Khoury T, Zirpoli GR, Bshara W, Davis W, Omilian A, Nair P, Ondracek RP, Cheng TD, Miller CR<\/strong>, Hwang H, Thorne LB, O\u2019Connor S, Bethea TN, Bell ME, Hu Z, Li Y, Kirk EL, Sun X, Ruiz-Narvaez EA, Perou CM, Palmer JR, Olshan AF, Ambrosone CB, Troester MA. Frequency of breast cancer subtypes among African American women in the AMBER consortium.\u00a0 Breast Cancer Research.\u00a0 20(1):12 Feb 2018.\u00a0 PMID: 29409530<\/a>\u00a0 PMCID: PMC5801839<\/a><\/li>\n
  10. Connolly NP, Shetty AC, Stokum JA, Hoeschele I, Siegel MB, Miller CR<\/strong>, Kim AJ, Ho CY, Davila E, Simard JM, Devine SE, Rossmeisl JH, Holland EC, Winkles JA, Woodworth GF. Cross-species transcriptional analysis reveals conserved and host-specific neoplastic processes in mammalian glioma.\u00a0 Scientific Reports.\u00a0 8(1):1180 Jan 2018.\u00a0 PMID: 29352201<\/a>\u00a0 PMCID: PMC5775420<\/a><\/li>\n
  11. Wu J, Frady LN, Bash RE, Cohen SM, Schorzman AN, Su YT, Irvin DM, Zamboni WC, Wang X, Frye SV, Ewend MG, Sulman EP, Gilbert MR, Earp HS, Miller CR<\/strong>. MerTK as a therapeutic target in glioblastoma.\u00a0 Neuro-oncology. 20(1):92-102 Jan 2018.\u00a0 PMID: 28605477<\/a> \u00a0PMCID:\u00a0 PMC5761530<\/a><\/li>\n<\/ol>\n

    2017<\/h3>\n
      \n
    1. Khagi S, Miller CR<\/strong>. Putting \u201cmultiforme\u201d back into glioblastoma: intratumoral transcriptome heterogeneity is a consequence of its complex morphology.\u00a0 Neuro-oncology.\u00a0 Neuro-oncology.\u00a0 19(12):1570-1571 Nov 2017.\u00a0 PMID: 29016836<\/a>\u00a0 PMCID: PMC5716077<\/a><\/li>\n
    2. McNeill RS<\/strong>,\u00a0Canoutas DA<\/strong>, Stuhlmiller TJ, Dhruv HD,\u00a0Irvin DM<\/strong>,\u00a0Bash RE<\/strong>, Angus SP, Herring LE, Simon JM,\u00a0Skinner KR<\/strong>, Limas JC, Chen X,\u00a0Schmid RS<\/strong>, Siegel MB, Van Swearingen AED,\u00a0Hadler MJ, Sulman EP, Sarkaria JN, Anders CK, Graves LM, Berens ME, Johnson GL,\u00a0Miller CR<\/strong>. Combination therapy with potent PI3K and MAPK inhibitors\u00a0overcomes\u00a0adaptive kinome resistance to single agents in preclinical models of glioblastoma. Neuro-oncology. 19(11):1469-1480 Oct 2017. PMID: 28379424<\/a> \u00a0PMCID:\u00a0 PMC5737415<\/a><\/li>\n
    3. Van Swearingen AED, Sambade MJ, Siegel MB, Sud S,\u00a0McNeill RS<\/strong>,\u00a0Bevill SM, Chen X,\u00a0Bash RE, Mounsey L,\u00a0Golitz\u00a0BT, Santos C, Deal A, Parker JS, Rashid N,\u00a0Miller CR<\/strong>, Johnson GL, Anders CK.\u00a0 Combined kinase inhibitors of MEK1\/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.\u00a0 Neuro-oncology.\u00a0 19(11):1481-1493 Oct 2017.\u00a0 PMID: 28486691<\/a> \u00a0PMCID:\u00a0 PMC5737524<\/a><\/li>\n
    4. Madden AJ, Oberhardt B, Lockney D, Santos C, Vennam P, Arney D, Franzen S, Lommel SA, Miller CR<\/strong>, Gehrig P, Zamboni WC. Pharmacokinetics and efficacy of doxorubicin-loaded plant virus nanoparticles in preclinical models of cancer. Nanomedicine. 12(20):2519-2532 Oct 2017.\u00a0\u00a0PMID: 28952882<\/a><\/li>\n
    5. Vitucci M<\/strong>*,\u00a0Irvin DM<\/strong>*,\u00a0McNeill RS<\/strong>,\u00a0Schmid RS<\/strong>, Simon JM, Dhruv HD, Siegel MB,\u00a0Werneke AM<\/strong>,\u00a0Bash RE<\/strong>, Kim S, Berens ME,\u00a0Miller CR<\/strong>.\u00a0 Genomic profiles of low-grade murine gliomas evolve during progression to glioblastoma.\u00a0 Neuro-oncology.\u00a0 19(9):1237-1257 Sep 2017.\u00a0 *Co-first authors.\u00a0 PMID: 28398584<\/a> \u00a0PMCID:\u00a0 PMC5570221<\/a><\/li>\n
    6. Khoury T, Zirpoli G, Cohen SM, Geradts J, Omilian A, Davis W, Bshara W, Miller R, Mathews MM, Troester M, Palmer JR, Ambrosone CB. Ki-67 Expression in Breast Cancer Tissue Microarrays: Assessing Tumor Heterogeneity, Concordance With Full Section, and Scoring Methods. American Journal of Clinical Pathology. 148(2):108-118 Aug 2017. PMID: 28898983<\/a> \u00a0PMCID:\u00a0 PMC5848430<\/a><\/li>\n
    7. Stowe HB, Miller CR<\/strong>, Wu J<\/strong>, Randazzo DM, Ju AW. Pineal region glioblastoma, a case report and literature review. Frontiers in Oncology. 7:123 Jun 2017. PMID: 28660172<\/a>\u00a0 PMCID: PMC5466962<\/a><\/li>\n
    8. Kodack DP, Askoxylakis V, Ferraro GB, Sheng Q, Badeaux M, Goel S, Qi X, Shankaraiah R, Cao ZA, Ramjiawan RR, Bezwada D, Patel B, Song Y, Costa C, Naxerova K, Wong CSF, Kloepper J, Das R, Tam A, Tanboon J, Duda DG, Miller CR<\/strong>, Siegel MB, Anders CK, Sanders M, Estrada MV, Schlegel R, Arteaga CL, Brachtel E, Huang A, Fukumura D, Engelman JA, Jain RK. The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. Science Translational Medicine. 9(391) May 2017. PMID: 28539475<\/a><\/li>\n
    9. Bago JR, Okolie O, Dumitru R, Ewend MG, Parker JS, Vander Werff R, Underhill TM,\u00a0Schmid RS<\/strong>,\u00a0Miller CR<\/strong>, Hingtgen SD. Tumor-homing cytotoxic human induced neural stem cells for cancer therapy. Science Translational Medicine. 9(375):eaah6510 Feb 2017. PMID:\u00a028148846<\/a><\/li>\n
    10. Irvin DM<\/strong>,\u00a0McNeill RS<\/strong>,\u00a0Bash RE<\/strong>,\u00a0Miller CR<\/strong>. Intrinsic astrocyte heterogeneity influences tumor growth in glioma mouse models. Brain Pathology. 27(1):36-50 Jan 2017. PMID: 26762242<\/a> \u00a0PMCID:\u00a0 PMC5322824<\/a><\/li>\n
    11. Kaiser-Rogers K, Trembath D, Miller CR<\/strong>.\u00a0 In situ hybridization.\u00a0 In:\u00a0 Reference Module in Neuroscience and Biobehavioral Psychology, Elsevier, 2017.\u00a0 Pages 1-7.\u00a0 ISBN 978-0-128-09324-5<\/a><\/li>\n<\/ol>\n

      2016<\/h3>\n<\/div>\n
        \n
      1. Okolie O, Bago JR,\u00a0Schmid RS<\/strong>,\u00a0Irvin DM<\/strong>,\u00a0Bash RE,\u00a0<\/strong>Miller CR*<\/b>, Hingtgen SD*.\u00a0 Reactive astrocytes potentiate tumor aggressiveness in murine glioma resection and recurrence model.\u00a0 Neuro-oncology. \u00a018(12):1622-1633 Dec 2016.\u00a0 *Co-senior authors\u00a0 PMID: 27298311<\/a>\u00a0 PMCID: PMC5791515<\/a><\/li>\n
      2. Hu P, Li Y, Nikolaishvili-Feinberg N, Scesa G, Bi Y, Pan D, Moore D, Bongarzone ER, Sands MS, Miller R<\/strong>, Kafri T. Hematopoietic stem cell transplantation and lentiviral vector-based gene therapy for Krabbe’s disease: Present convictions and future prospects. Journal of Neuroscience Research. 94(11):1152-1168 Nov 2016. PMID:\u00a0 27638600<\/a>\u00a0 PMCID:\u00a0 PMC5027985<\/a><\/li>\n
      3. McNeill RS<\/strong>,\u00a0Irvin DM<\/strong>,\u00a0Miller CR<\/strong>.\u00a0 BRAF mutations open doors to ENU-induced gliomagenesis.\u00a0 American Journal of Pathology. \u00a0186(10):2551-2554 Oct 2016.\u00a0 PMID: 27543966<\/a>\u00a0 PMCID: PMC5222976<\/a><\/li>\n
      4. LeBlanc AK, Mazcko C, Brown DB, Koehler JW, Miller AD,\u00a0Miller CR<\/b>, Bentley RT, Packer RA, Breen M, Boudreau B, Levine JM, Simpson MR, Halsey C, Kisseberth W, Rossmeisl JH, Dickinson PJ, Fan T, Corps K, Aldape K, Puduvalli V, Gilbert MR.\u00a0 Creation of an NCI Comparative Brain Tumor Consortium: Informing the translation of new knowledge from canine to human brain tumor patients. \u00a0Neuro-oncology.\u00a0 18(9):1209-1218 Sep 2016.\u00a0 PMID: 27179361<\/a>\u00a0 PMCID: PMC4999002<\/a><\/li>\n
      5. Schmid RS<\/strong>, Simon JM,\u00a0Vitucci M<\/strong>,\u00a0McNeill RS<\/strong>,\u00a0Bash RE<\/strong>,\u00a0Werneke AM<\/strong>,\u00a0Huey L<\/strong>,\u00a0White KK<\/strong>, Ewend MG,\u00a0Wu J<\/strong>,\u00a0Miller CR<\/b>.\u00a0 Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation, but resistant to temozolomide.\u00a0 Neuro-oncology.\u00a0 18(7):962-973 Jul 2016.\u00a0 PMID:\u00a026826202<\/a>\u00a0 PMCID:\u00a0PMC4896545<\/a><\/li>\n
      6. Allott EH, Cohen SM, Geradts J, Sun X, Khoury T, Bshara W, Zirpoli G,\u00a0Miller CR<\/b>, Hwang H, Thorne L, O\u2019Connor S, Tse CK, Bell MB, Hu Z, Li Y, Kirk EL, Bethea T, Perou CM, Palmer JR, Ambrosone CB, Olshan AF, Troester MA.\u00a0 Performance of three biomarker immunohistochemistry for intrinsic breast cancer subtyping in the AMBER consortium.\u00a0 Cancer Epidemiology, Biomarkers & Prevention.\u00a0 25(3):470-478 Mar 2016.\u00a0 PMID:\u00a026711328<\/a>\u00a0 PMCID:\u00a0PMC4779705<\/a><\/li>\n
      7. Bago JR, Alfonso-Pecchio A, Okolie O, Dumitru R, Rinkenbaugh A, Baldwin AS,\u00a0Miller CR<\/b>, Magness ST, Hingtgen SD.\u00a0 Therapeutically engineered induced neural stem cells are tumor-homing and inhibit progression of glioblastoma.\u00a0 Nature Communications.\u00a0 7:10593 Feb 2016.\u00a0 PMID:\u00a026830441<\/a>\u00a0PMCID:\u00a0PMC4740908<\/a><\/li>\n
      8. Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, Rao A, Grifford M, Cherniack AD, Zhang H, Poisson L, Rao A, Mikkelsen T, Lau CC, Yung WKA, Rabadan R, Huse J, Brat DJ, Lehman N, Rao G, Meyerson M, Beroukhim R, Cooper L, Akbani R, Wrensch M, Haussler D, Aldape KD, Laird PW, Gutmann DH,\u00a0Cancer Genome Atlas Research Network<\/b>, Noushmehr H, Iavarone A, Verhaak RGW.\u00a0 Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma.\u00a0 Cell.\u00a0 164(3):550-563 Jan 2016.\u00a0 PMID:\u00a026824661<\/a>\u00a0 PMCID:\u00a0PMC4754110<\/a><\/li>\n<\/ol>\n
        \n

        2015<\/h3>\n<\/div>\n
          \n
        1. Prabhu A, Sarcar B,\u00a0Miller CR<\/b>, Kim SH,\u00a0<\/b>Nakano I, Forsyth P, Chinnaiyan P.\u00a0 Ras-mediated modulation of pyruvate dehydrogenase activity regulates mitochondrial reserve capacity and contributes to glioblastoma tumorigenesis.\u00a0 Neuro-oncology.\u00a0 17(9):1220-1230 Sep 2015.\u00a0 PMID:\u00a025712957<\/a>\u00a0 PMCID:\u00a0PMC4588752<\/a><\/li>\n
        2. Garcia I, Crowther AJ, Gama V,\u00a0Miller CR<\/b>, Deshmukh M, Gershon TR. \u00a0Erratum: Bax-deficiency prolongs cerebellar neurogenesis, accelerates medulloblastoma formation and paradoxically increases both malignancy and differentiation.\u00a0 Oncogene.\u00a0 34(29):3881 Jul 2015.\u00a0 PMID:\u00a0\u00a026179456<\/a><\/li>\n
        3. Cancer Genome Atlas Research Network<\/b>.\u00a0 Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas.\u00a0 New England Journal of Medicine.\u00a0 372(26):2481-2498.\u00a0 Jun 2015.\u00a0 PMID:\u00a026061751<\/a>\u00a0 PMCID:\u00a0PMC4530011<\/a><\/li>\n
        4. Carson CC, Moschos SJ, Edmiston SN, Darr DB, Nikoliashvili-Feinberg N, Groben PA, Zhou X, Kuan PF, Pandey S, Chan KT, Jordan JL, Hao H, Frank JS, Hopkinson DA, Gibbs DC, Alldredge VD, Parrish E, Hanna SC, Berkowitz P, Rubenstein DS,\u00a0Miller CR<\/b>, Bear JE, Ollila DW, Sharpless NE, Conway K, Thomas NE.\u00a0 IL-2 inducible T-cell kinase, a novel therapeutic target in melanoma.\u00a0 Clinical Cancer Research.\u00a0 21(9):2167-2176 May 2015.\u00a0 PMID:\u00a025934889<\/a>\u00a0 PMCID:\u00a0PMC4418029<\/a><\/li>\n
        5. Karginova O, Siegel MB, Adamo B, Deal AM, Van Swearingen AED, Nikolaishvili-Feinberg N, Parker JS, Santos CM, Darr D, Bash R, Sandison K, Zamboni WC,\u00a0Miller CR<\/b>, Anders CK.\u00a0 Efficacy of carboplatin alone and in combination with ABT888 in intracranial murine models of BRCA-mutated and BRCA-wild-type triple negative breast cancer.\u00a0 Molecular Cancer Therapeutics.\u00a0 14(4):920-930 Apr 2015. PMID:\u00a025824335<\/a>\u00a0 PMCID:\u00a0PMC4394032<\/a><\/li>\n
        6. Knight ER, Patel EY, Flowers CA, Crowther AJ, Ting JP,\u00a0Miller CR<\/b>, Gershon TR, Deshmukh M.\u00a0 ASC deficiency suppresses proliferation and prevents medulloblastoma incidence.\u00a0 Oncogene.\u00a0 34(3):394-402 Jan 2015.\u00a0 PMID:\u00a024469054<\/a>\u00a0 PMCID:\u00a0PMC4520702<\/a><\/li>\n
        7. McNeill RS<\/strong>,\u00a0Vitucci M<\/strong>,\u00a0Wu J<\/strong>,\u00a0Miller CR<\/b>.\u00a0 Contemporary murine models in preclinical astrocytoma drug development.\u00a0 Neuro-oncology.\u00a0 17(1):12-28 Jan 2015.\u00a0 PMID:\u00a025246428<\/a>\u00a0 PMCID:\u00a0PMC4483055<\/a><\/li>\n<\/ol>\n

          2014<\/h3>\n
            \n
          1. Song G, Darr D, Santos CM, Ross M, Valdivia A, Jordan J, Midkiff BR, Cohen SM, Feinberg NN,\u00a0Miller CR<\/b>, Tarrant TK, Rogers AB, Dudley AC, Perou CM, Zamboni WC.\u00a0 Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models.\u00a0 Clinical Cancer Research.\u00a0 20(23):6083-6095 Dec 2014.\u00a0 PMID:\u00a025231403<\/a>\u00a0 PMCID:\u00a0PMC4565518<\/a><\/li>\n
          2. Galvao RP, Kasina A,\u00a0McNeill RS<\/strong>, Harbin JE, Foreman O, Verhaak RGW, Nishiyama A,\u00a0Miller CR<\/b>, Zong H.\u00a0 Transformation of quiescent adult oligodendrocyte precursor cells into malignant glioma through a multi-step reactivation process.\u00a0 Proceedings of the National Academy of Science USA.\u00a0 111(40):E4214-E4223 Oct 2014.\u00a0 PMID:\u00a025246577<\/a>\u00a0 PMCID:\u00a0PMC4210043<\/a><\/li>\n
          3. McNeill RS<\/strong>,\u00a0Schmid RS<\/strong>,\u00a0Bash RE<\/strong>,\u00a0Vitucci M<\/strong>,\u00a0White KK<\/strong>,\u00a0Werneke AM<\/strong>,\u00a0Constance BH<\/strong>,\u00a0Huff B<\/strong>,\u00a0Miller CR<\/b>.\u00a0 Modeling astrocytoma pathogenesis in vitro and in vivo using cortical astrocytes or neural stem cells from conditional, genetically engineered mice.\u00a0 Journal of Visualized Experiments.\u00a0 90:e51763 Aug 2014.\u00a0 PMID:\u00a025146643<\/a>.<\/li>\n
          4. Brooks SA, Brannon AR, Parker JS, Fisher JC, Sen O, Kattan MW, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P,\u00a0Miller CR<\/b>, Nielsen ME, Rathmell WK.\u00a0 ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma.\u00a0 European Urology.\u00a0 66(1):77-84 Jul 2014.\u00a0 PMID:\u00a024613583<\/a>\u00a0 PMCID:\u00a0PMC4058355<\/a><\/li>\n
          5. Nikolaishvilli-Feinberg N, Cohen SM, Midkiff B, Zhou Y, Olorvida M, Ibrahim JG, Omolo B, Shields JM, Thomas NE, Groben PA, Kaufmann WK,\u00a0Miller CR<\/b>.\u00a0 Development of DNA damage response signaling biomarkers using automated, quantitative image analysis.\u00a0 Journal of Histochemistry and Cytochemistry.\u00a0 62(3):185-196 Mar 2014.\u00a0 PMID:\u00a024309508<\/a>\u00a0 PMCID:\u00a0PMC3935445<\/a><\/li>\n
          6. Zhou B, Damrauer JS, Bailey ST, Hadzic T, Jeong Y, Clark K, Fan C, Murphy L, Lee CY, Troester MA,\u00a0Miller CR<\/b>, Jin J, Darr D, Perou CM, Levine RL, Diehn M, Kim WY.\u00a0 Erythropoietin promotes breast cancer tumorigenesis through tumor initiating cell self-renewal.\u00a0 Journal of Clinical Investigation.\u00a0 124(2):553-563 Feb 2014.\u00a0 PMID:\u00a024435044<\/a>\u00a0 PMCID:\u00a0PMC3904607<\/a><\/li>\n
          7. Malin D, Strekalova E, Petrovic V, Deal AM, Ahmad AA, Adamo B,\u00a0Miller CR<\/b>, Ugolkov A, Livasy C, Fritchie K, Hamilton EP, Blackwell K, Geradts J, Ewend M, Carey LA, Shusta EV, Anders CK, Cryns VL.\u00a0 \u03b1B-crystallin: A novel regulator of breast cancer metastasis to the brain.\u00a0 Clinical Cancer Research.\u00a0 20(1):56-67 Jan 2014:\u00a0 PMID:\u00a024132917<\/a>\u00a0 PMCID:\u00a0PMC3973485<\/a><\/li>\n
          8. Huse JT, Wallace M, Aldape KD, Berger MS, Bettegowda C, Brat DJ, Cahill DP, Cloughesy T, Haas-Kogan DA, Marra M,\u00a0Miller CR<\/b>, Nelson SJ, Salama SR, Soffietti R, Wen PY, Yip S, Yen K, Costello JF, Chang S.\u00a0 Where are we now?\u00a0 And where are we going?\u00a0 A report from the Accelerate Brain Cancer Cure (ABC2<\/sup>) low-grade glioma workshop.\u00a0 Neuro-oncology.\u00a0 16(2):173-178 Jan 2014.\u00a0 PMID:\u00a024305708<\/a>\u00a0 PMCID:\u00a0PMC3895389<\/a><\/li>\n
          9. Kaiser-Rogers C, Trembath D,\u00a0Miller CR<\/b>.\u00a0 In situ hybridization.\u00a0 In:\u00a0 Aminoff MJ and Dardoff RB (eds), Encyclopedia of Neurological Sciences, 2nd<\/sup>\u00a0Ed., Vol. 2, Oxford: Academic Press, 2014.\u00a0 Chapter 593. Pages 699-704.\u00a0 ISBN\u00a0978-0-123-85157-4<\/a><\/li>\n<\/ol>\n

            2013<\/h3>\n
              \n
            1. Huff LP, DeCristo MJ, Trembath D, Kuan PF, Yim M, Liu J, Cook DR,\u00a0Miller CR<\/b>, Der CJ, Cox AD.\u00a0 The role of Ect2 nuclear RhoGEF activity in ovarian cancer cell transformation.\u00a0 Genes & Cancer.\u00a0 4(11-12):460-475 Nov\/Dec 2013.\u00a0 PMID:\u00a024386507<\/a>\u00a0 PMCID:\u00a0PMC3877668<\/a><\/li>\n
            2. Kimura M, Lee Y,\u00a0Miller R<\/b>, Castillo M.\u00a0 Glioblastoma multiforme: relationship to subventricular zone and recurrence.\u00a0 Neuroradiology Journal. 26(5):542-547 Oct 2013.\u00a0 PMID:\u00a024199814<\/a>\u00a0 PMCID:\u00a0PMC4202832<\/a><\/li>\n
            3. Song Y, Zhang Q, Kutlu B, Difilippantonio S,\u00a0Bash R<\/strong>, Gilbert D, Yin C, O\u2019Sullivan TN, Yang C, Kozlov S, Bullitt E, McCarthy KD, Kafri T, Louis DN,\u00a0Miller CR<\/b>, Hood L, Van Dyke T.\u00a0 Evolutionary etiology of high-grade astrocytomas.\u00a0 Proceedings of the National Academy of Science USA.\u00a0 110(44):17933-17938 Oct 2013. \u00a0PMID:\u00a024114272<\/a>\u00a0PMCID:\u00a0PMC3816471<\/a><\/li>\n
            4. Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro, Friedman W, Andrews DW, Guha A, Iacocca M, O\u2019Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L, and\u00a0Cancer Genome Atlas Research Network<\/b>.\u00a0 The somatic genomic landscape of glioblastoma.\u00a0 Cell.\u00a0 155(2):462-477 Oct 2013. \u00a0PMID:\u00a024120142<\/a>\u00a0 PMCID:\u00a0PMC3910500<\/a><\/li>\n
            5. Vitucci M<\/strong>*, Karpinich NO*,\u00a0Bash RE<\/strong>,\u00a0Werneke AM<\/strong>,\u00a0Schmid RS<\/strong>,\u00a0White KK<\/strong>,\u00a0McNeill RS<\/strong>,\u00a0Huff B<\/strong>, Wang S, Van Dyke T,\u00a0Miller CR<\/b>.\u00a0 Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis.\u00a0 *Co-first authors.\u00a0 Neuro-oncology.\u00a0 15(10):1317-1329 Oct 2013.\u00a0 PMID:\u00a023814263<\/a>\u00a0 PMCID:\u00a0PMC3779038<\/a><\/li>\n
            6. Rutledge WC, Kong J, Gao J, Gutman DA, Cooper L, Appin C, Park Y, Scarpace L, Mikkelsen T, Cohen ML, Aldape KD, McLendon RE, Lehman NL,\u00a0Miller CR<\/b>, Schniederjan MJ, Brennan CW, Moreno CS, Staltz JH, Brat DJ.\u00a0 Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class.\u00a0 Clinical Cancer Research.\u00a0 19(18):4951-4960 Sep 2013. \u00a0PMID:\u00a023864165<\/a>\u00a0 PMCID:\u00a0PMC3865611<\/a><\/li>\n
            7. Raghunathan A, Wani K, Armstrong TS, Ver-Bolanos E, Fouladi M, Gilbertson R, Gajjar A, Goldman S, Lehman NL, Metellus P, Mikkelsen T, Necesito-Reyes MJ, Omuro A, Packer RJ, Partap S, Pollack IF, Prados MD, Robins HI, Soffietti R, Wu J,\u00a0Miller CR<\/b>, Gilbert MR, Aldape KD, Collaborative Ependymoma Research Network.\u00a0 Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system.\u00a0 Brain Pathology. \u00a023(5):584-594 Sep 2013.\u00a0 PMID:\u00a023452038<\/a><\/li>\n
            8. Wilkerson MD*, Schallheim JM*, Hayes DN*, Roberts PJ, Bastein R, Mullins M, Yin X,\u00a0Miller CR<\/b>, Thorne LB, Funkhouser WK, Fan C, Hayward MC, Bayer S, Perou CM, Bernard PS.\u00a0 Prediction of lung cancer histological types by qRT-PCR gene expression in FFPE specimens.\u00a0 *Co-first authors.\u00a0 Journal of Molecular Diagnostics.\u00a0 15(4):485-497 Jul 2013.\u00a0 PMID:\u00a023701907<\/a>\u00a0 PMCID:\u00a0PMC3699698<\/a><\/li>\n
            9. Gershon TR, Crowther AJ, Liu H,\u00a0Miller CR<\/b>, Deshmukh M.\u00a0 Cerebellar granule neuron progenitors are the source of Hk2 in the postnatal cerebellum.\u00a0 Cancer and Metabolism.\u00a0 1(1):15 Jun 2013.\u00a0 PMID:\u00a024280296<\/a>\u00a0 PMCID:\u00a0PMC4178205<\/a><\/li>\n
            10. Anders CK, Adamo B, Karginova O, Deal AM, Rawal S, Walsh M, Darr D, Schorzman A, Santos C, Bash R, Kafri T, Carey L,\u00a0Miller CR<\/b>, Perou CM, Sharpless N, Zamboni WC.\u00a0 Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer.\u00a0 PLoS One.\u00a0 8(5): e61359 May 2013. \u00a0PMID:\u00a023650496<\/a>\u00a0 PMCID:\u00a0PMC3641071<\/a><\/li>\n
            11. Garcia I, Crowther AJ, Gama V,\u00a0Miller CR<\/b>, Deshmukh M, Gershon TR. \u00a0Bax-deficiency prolongs cerebellar neurogenesis, accelerates medulloblastoma formation and paradoxically increases both malignancy and differentiation.\u00a0 Oncogene.\u00a0 32(18):2304-2314 May 2013.\u00a0 PMID:\u00a0\u00a022710714<\/a>\u00a0 PMCID:\u00a0PMC3449008<\/a><\/li>\n
            12. Schlegel J, Sambade MJ, Sather S, Moschos SJ, Tan AC, Winges A, DeRyckere D, Carson CC, Trembath DG, Tentler JJ, Eckhardt SG, Kuan PF, Hamilton RL, Duncan LM,\u00a0Miller CR<\/b>, Nikolaishvili-Feinberg N, Midkiff BR, Liu J, Zhang W, Yang C, Wang X, Frye SV, Earp HS, Shields JM, Graham DK.\u00a0 MERTK receptor tyrosine kinase is a therapeutic target in melanoma.\u00a0 Journal of Clinical Investigation.\u00a0 123(5):2257-2267 Apr 2013.\u00a0 PMID:\u00a023585477<\/a>\u00a0\u00a0PMCID:\u00a0PMC3639697<\/a><\/li>\n
            13. Hanna SC, Krishnan B, Bailey ST, Moschos SJ, Kuan PF, Shimamura T, Osborne LD, Siegel MB, Duncan LM, O\u2019Brien ET, Superfine R,\u00a0Miller CR<\/b>, Simon MC, Wong KK, Kim WY.\u00a0 HIF1\u03b1 and HIF2\u03b1 independently activate SRC to promote melanoma metastases.\u00a0 Journal of Clinical Investigation.\u00a0 123(5):2078-2093 Apr 2013.\u00a0 PMID:\u00a023563312<\/a>\u00a0\u00a0PMCID:\u00a0PMC3635738<\/a><\/li>\n
            14. Di L, Byun JS, Wong MM, Wakano C, Taylor T, Bilke S, Baek S, Hunter K, Yang H, Lee M, Zvosec C, Khramtsova G, Cheng F, Perou CM,\u00a0Miller CR<\/b>, Raab R, Olopade OI, Gardner K.\u00a0 Genome-wide profiles of CtBP link metabolism with genome stability and epithelial reprogramming in breast cancer.\u00a0 Nature Communications.\u00a0 4:1449 Mar 2013.\u00a0 PMID:\u00a023385593<\/a>\u00a0\u00a0PMCID:\u00a0PMC3768144<\/a><\/li>\n
            15. Gershon TR, Crowther AJ, Tikunov A, Garcia I, Annis R, Yuan H,\u00a0Miller CR<\/b>, Macdonald J, Olson J, Deshmukh M.\u00a0 Hexokinase-2 mediated aerobic glycolysis is integral to cerebellar neurogenesis and required for pathogenesis of medulloblastoma.\u00a0 Cancer and Metabolism.\u00a0 1(1):2 Jan 2013.\u00a0 PMID:\u00a024280485<\/a>\u00a0 PMCID:\u00a0PMC3782751<\/a><\/li>\n
            16. Grilley-Olson JE, Hayes DN, Moore DT, Leslie KO, Wilkerson MD, Qaqish BF, Hayward MC, Cabanski CR, Yin X, Socinski MA, Stinchcombe TE, Thorne LB, Allen TC, Banks PM, Beasley MB, Borczuk AC, Cagle PT, Christensen R, Colby TV, Deblois GG, Elmberger G, Graziano P, Hart CF, Jones KD, Maia DM,\u00a0Miller CR<\/b>, Nance KV, Travis WD, Funkhouser WK.\u00a0 Validation of interobserver agreement in lung cancer assessment: hematoxylin and eosin diagnostic reproducibility for non-small cell lung cancer – The 2004 World Health Organization classification and therapeutically relevant subsets.\u00a0 Archives of Pathology & Laboratory Medicine. \u00a0137(1):32-40 Jan 2013.\u00a0 PMID:\u00a0\u00a022583114<\/a><\/li>\n<\/ol>\n

              2012<\/h3>\n
                \n
              1. Dellon ES, Chen X,\u00a0Miller CR<\/b>, Woosley JT, Shaheen NJ.\u00a0 Diagnostic utility of major basic protein, eotaxin-3, and leukotriene enzyme staining in eosinophilic esophagitis.\u00a0 American Journal of Gastroenterology.\u00a0 107(10):1503-1511 Oct 2012.\u00a0 PMID:\u00a0\u00a022777338<\/a>\u00a0 PMCID:\u00a0PMC3744826<\/a><\/li>\n
              2. Liu W, Monahan KB, Pfefferle AD, Shimamura T, Sorrentino J, Chan KT, Roadcap DW, Ollila DW, Thomas NE, Castrillon DH,\u00a0Miller CR<\/b>, Perou CM, Wong KK, Bear JE, Sharpless NE.\u00a0 LKB1\/STK11 inactivation leads to expansion of a pro-metastatic tumor sub-population in melanoma.\u00a0 Cancer Cell.\u00a0 21(2):751-764 Jun 2012.\u00a0 PMID:\u00a0\u00a022698401<\/a>\u00a0\u00a0PMCID:\u00a0PMC3660964<\/a><\/li>\n
              3. Schmid RS, Vitucci M,\u00a0Miller CR<\/b>.\u00a0 Genetically engineered mouse models of diffuse gliomas.\u00a0 Brain Research Bulletin.\u00a0 88(1):72-79 May 2012.\u00a0 PMID:\u00a021684324<\/a><\/li>\n
              4. Wilkerson MD, Yin X, Walter V, Zhao N, Cabanski CR, Hayward MC,\u00a0Miller CR<\/b>, Socinski MA, Parsons AM, Thorne LB, Haithcock BE, Veeramachaneni NK, Funkhouser WK, Randell SH, Bernard PS, Perou CM, Hayes DN.\u00a0 Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation.\u00a0 PLoS One.\u00a0 7(5):e36530 May 2012.\u00a0 PMID:\u00a022590557<\/a>\u00a0 PMCID:\u00a0PMC3349715<\/a><\/li>\n
              5. Pei Y, Moore CE, Wang J, Tewari AK, Eroshkin A, Cho YJ, Witt H, Korshunov A, Read TA, Sun JL, Schmitt EM,\u00a0Miller CR<\/b>, Buckley AF, McLendon RE, Westbrook TF, Northcott PA, Taylor MD, Pfister SM, Febbo PG, Wechsler-Reya RJ.\u00a0 An animal model of MYC-driven medulloblastoma.\u00a0 Cancer Cell.\u00a0 21(2):155-167 Feb 2012.\u00a0 PMID:\u00a022340590<\/a>\u00a0\u00a0PMCID:\u00a0PMC3285431<\/a><\/li>\n
              6. Dellon ES, Bower JJ, Keku TO, Chen L,\u00a0Miller CR<\/b>, Woosley JT, Orlando RC, Shaheen NJ.\u00a0 Markers of tyrosine kinase activity in eosinophilic esophagitis: A pilot study of the FIP1L1-PDGFR\u03b1 fusion gene, pERK 1\/2, and pSTAT5.\u00a0 Diseases of the Esophagus.\u00a0 25(2):166-174 Feb 2012.\u00a0 PMID:\u00a021819482<\/a>\u00a0\u00a0PMCID:\u00a0PMC3213309<\/a><\/li>\n<\/ol>\n

                \u00a02011<\/h3>\n
                  \n
                1. Adamo B, Deal AM, Burrows E, Geradts J, Hamilton E, Blackwell KL, Livasy C, Fritchie K, Prat A, Harrell JC, Ewend MG, Carey LA,\u00a0Miller CR<\/b>*, Anders CK*.\u00a0 Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases.\u00a0 Breast Cancer Research.\u00a0 13(6):R125 Dec 2011.\u00a0 *Co-senior authors.\u00a0 PMID:\u00a022132754<\/a>\u00a0 PMCID:\u00a0PMC3326567<\/a><\/li>\n
                2. Ang MK, Patel MR, Yin XY, Sundaram S, Fritchie K, Zhao N, Liu Y, Freemerman AJ, Wilkerson MD, Walter V, Weissler MC, Shockley WW, Couch ME, Zanation AM, Hackman T, Chera BS, Harris SL,\u00a0Miller CR<\/b>, Thorne LB, Hayward MC, Funkhouser WK, Olshan AF, Shores CG, Makowski L, Hayes DN.\u00a0 High XRCC1 expression is associated with poorer survival in patients with head and neck squamous cell carcinoma.\u00a0 Clinical Cancer Research.\u00a0 17(20):6542-6552 Oct 2011.\u00a0 PMID:\u00a021908577<\/a>\u00a0\u00a0PMCID:\u00a0PMC3725262<\/a><\/li>\n
                3. Stevens EV, Banet N, Onesto C, Plachco A, Alan JK, Nikolaishvili-Feinberg N, Midkiff BR, Kuan PF, Liu J,\u00a0Miller CR<\/b>, Vigil D, Graves LM, Der CJ.\u00a0 RhoGDI2 antagonizes ovarian carcinoma growth, invasion and metastasis.\u00a0 Small GTPases.\u00a0 2(4):202-210 Jul 2011. \u00a0PMID:\u00a022145092<\/a>\u00a0 PMCID:\u00a0PMC3225909<\/a><\/li>\n
                4. Anders CK, Deal AM,\u00a0Miller CR<\/b>, Khorram C, Meng H, Burrows E, Livasy C, Fritchie K, Ewend MG, Perou CM, Carey LA.\u00a0 The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases.\u00a0 Cancer.\u00a0 117(8):1602-1611 Apr 2011.\u00a0 PMID:\u00a021472708<\/a>\u00a0 PMCID:\u00a0PMC4265570<\/a><\/li>\n
                5. Vitucci M<\/strong>, Hayes DN,\u00a0Miller CR<\/b>.\u00a0 Gene expression profiling of gliomas:\u00a0 Merging genomic and histopathological classification for personalised therapy.\u00a0 British Journal of Cancer.\u00a0 104(4):545-553 Feb 2011.\u00a0 PMID:\u00a021119666<\/a>\u00a0 PMCID:\u00a0PMC3049580<\/a><\/li>\n
                6. Dellon ES, Chen X,\u00a0Miller CR<\/b>, Fritchie KJ,\u00a0 Rubinas TC, Woosley JT, Shaheen NJ.\u00a0 Tryptase staining of mast cells may differentiate eosinophilic esophagitis from gastroesophageal reflux disease.\u00a0 American Journal of Gastroenterology.\u00a0 106(2):264-271 Feb 2011.\u00a0 PMID:\u00a020978486<\/a>\u00a0 PMCID:\u00a0PMC4372242<\/a><\/li>\n
                7. Horbinski C,\u00a0Miller CR<\/b>, Perry A.\u00a0 Gone FISHing: Clinical lessons learned in brain tumor molecular diagnostics over the last decade.\u00a0 Brain Pathology.\u00a0 21(1):57-73 Jan 2011.\u00a0 PMID:\u00a021129060<\/a><\/li>\n<\/ol>\n

                  2010<\/h3>\n
                    \n
                  1. Wilkerson MD, Yin X, Hoadley KA, Liu Y, Hayward MC, Cabanski CR, Muldrew K,\u00a0Miller CR<\/b>, Randell SH, Socinski MA, Parsons AM, Funkhouser WF, Lee CB, Roberts PJ, Thorne L, Bernard PS, Perou CM, Hayes DN.\u00a0 Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types.\u00a0 Clinical Cancer Research.\u00a0 16(19):4864-4875 Oct 2010.\u00a0 PMID\u00a020643781<\/a>\u00a0 PMCID:\u00a0PMC2953768<\/a><\/li>\n
                  2. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD,\u00a0Miller CR<\/b>, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O\u2019Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN and Cancer Genome Atlas Research Network.\u00a0 Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.\u00a0 Cancer Cell.\u00a0 17(1):98-110 Jan 2010.\u00a0 PMID:\u00a020129251<\/a>\u00a0 PMCID:\u00a0PMC2818769<\/a><\/li>\n<\/ol>\n

                    2009<\/h3>\n
                      \n
                    1. Goodgame B, Viswanathan A, Zoole J, Gao F,\u00a0Miller CR<\/b>, Subramanian J, Meyers BF, Patterson GA, Govindan R.\u00a0 Risk of recurrence of resected stage I non-small cell lung cancer in elderly patients as compared with younger patients.\u00a0 Journal of Thoracic Oncology.\u00a0 4(11):1370-1374 Nov 2009.\u00a0 PMID:\u00a019692932<\/a><\/li>\n
                    2. Perry A,\u00a0Miller CR<\/b>, Gujrati M, Scheithauer BW, Jost SC, Raghavan R, Qian J, Cochran EJ, Huse JT, Holland EC, Burger PC, Rosenblum MK.\u00a0 Malignant gliomas with primitive neuroectodermal tumor-like components: A clinicopathologic and genetic study of 53 cases.\u00a0 Brain Pathology.\u00a0 19(1):81-90 Jan 2009.\u00a0 PMID:\u00a018452568<\/a><\/li>\n
                    3. Buchsbaum DJ,\u00a0Miller CR<\/b>,\u00a0<\/b>McNally LR, Kaliberov SA.\u00a0 Cancer gene therapy.\u00a0 In:<\/i>\u00a0Oldham RK and Dillman RO (eds), Principles of Cancer Biotherapy, 5th<\/sup>\u00a0Ed., Dordrecht: Kluwer, 2009.\u00a0 Chapter 19: Pages 589-612.\u00a0 ISBN\u00a0978-90-481-2277-6<\/a>.<\/li>\n
                    4. Miller CR<\/b>, Karpinich NO, Zhang Q, Bullitt E, Kozlov S, and Van Dyke T.\u00a0 Modeling astrocytomas in a family of inducible genetically engineered mice: implications for preclinical cancer drug development.\u00a0 In: Van Meir EG (ed), CNS Cancer, Models, Prognostic Factors, and Targets, 1st<\/sup>Ed., Cambridge: Springer, 2009. \u00a0Chapter 7: Pages 119-145.\u00a0 ISBN\u00a0978-1-60327-552-1<\/a>.<\/li>\n<\/ol>\n

                      2008<\/h3>\n
                        \n
                      1. Yu J,\u00a0Miller R<\/b>, Zhang W, Sharma M, Holtschlag V, Watson MA, McLeod HL.\u00a0 Copy-number analysis of topoisomerase and thymidylate synthase genes in frozen and FFPE DNAs of colorectal cancers.\u00a0 Pharmacogenomics. 9(10):1459-1466 Oct 2008.\u00a0 PMID:\u00a018855534<\/a>\u00a0 PMCID:\u00a0PMC2575840<\/a><\/li>\n
                      2. Trembath D,\u00a0Miller CR<\/b>, Perry A.\u00a0 Grey zones in brain tumor classification:\u00a0 Evolving concepts.\u00a0 Advances in Anatomic Pathology 15(5):287-297 Sep 2008.\u00a0 PMID:\u00a018724102<\/a><\/li>\n
                      3. Goodgame B, Viswanathan A,\u00a0Miller CR<\/b>, Gao F, Meyers B, Battafarano RJ, Patterson A, Cooper J, Guthrie TJ, Bradley J, Pillot G, Govindan R.\u00a0 A clinical model to estimate recurrence risk in resected stage I non-small cell lung cancer.\u00a0 American Journal of Clinical Oncology.\u00a0 31(1):22-28 Feb 2008.\u00a0 PMID:\u00a018376223<\/a><\/li>\n<\/ol>\n

                        2007<\/h3>\n
                          \n
                        1. Lim WT, Zhang WH,\u00a0Miller CR<\/b>, Watters JW, Gao F, Viswanathan A, Govindan R, McLeod HL.\u00a0 PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer.\u00a0 Oncology Reports.\u00a0 17(4):853-857 Apr 2007.\u00a0 PMID:\u00a017342327<\/a><\/li>\n
                        2. Yuan L, Siegel M, Choi K, Khosla C,\u00a0Miller CR<\/b>, Jackson EN, Piwnica-Worms D, Rich KM.\u00a0 Tissue transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. \u00a0Oncogene 26(18):2563-2573 Apr 2007.\u00a0 PMID:\u00a017099729<\/a><\/li>\n
                        3. Miller CR<\/b>\u00a0and Perry A.\u00a0 Glioblastoma:\u00a0 Morphological and molecular genetic diversity.\u00a0 Archives of Pathology and Laboratory Medicine 131(3):397-406 Mar 2007.\u00a0 PMID:\u00a017516742<\/a><\/li>\n
                        4. Miller CR<\/b>\u00a0and McLeod HL.\u00a0 Pharmacogenomics of cancer chemotherapy-induced toxicity.\u00a0 Journal of Supportive Oncology 5(1):9-14 Jan 2007.\u00a0 PMID:\u00a017265780<\/a><\/li>\n
                        5. Vadivelu S, Mangano FT,\u00a0Miller CR<\/b>, Leonard JR.\u00a0 Multifocal Langerhans cell histiocytosis of the pediatric spine:\u00a0 a case report and literature review.\u00a0 Child’s nervous system.\u00a0 23(1)127-131 Jan 2007.\u00a0 PMID:\u00a017021733<\/a><\/li>\n<\/ol>\n

                          2006<\/h3>\n
                            \n
                          1. Miller CR<\/b>, Dunham C, Scheithauer B, Perry A.\u00a0 Significance of necrosis in grading of oligodendroglial neoplasms:\u00a0 A clinicopathological and genetic study of newly diagnosed high-grade gliomas.\u00a0 Journal of Clinical Oncology.\u00a0 24(34):5419-5426 Dec 2006.\u00a0 PMID:\u00a017135643<\/a><\/li>\n<\/ol>\n

                            2005<\/h3>\n
                              \n
                            1. Conrad C,\u00a0Miller CR<\/b>, Ji Y, Gomez-Manzano C, Bharara S, McMurray JS, Lang FF, Wong F, Sawaya R, Yung WK, Fueyo J.\u00a0 \u039424-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization.\u00a0 Cancer Gene Therapy 12(3):284-294 Mar 2005.\u00a0 PMID:\u00a015650766<\/a><\/li>\n<\/ol>\n

                              2004<\/h3>\n
                                \n
                              1. Miller CR\u00a0<\/b>and\u00a0<\/b>Perry A.\u00a0\u00a0Immunohistochemical differentiation of hemangioblastoma from metastatic clear cell renal carcinoma: An update<\/a>.\u00a0 Advances in Anatomic Pathology 11(6):325 Nov 2004.<\/li>\n
                              2. Miller CR\u00a0<\/b>and\u00a0<\/b>Perry A.\u00a0\u00a0CD34 and MAP-2 immunohistochemistry in the differential diagnosis of epilepsy-associated glioneuronal tumors<\/a>.\u00a0 Advances in Anatomic Pathology 11(6):326 Nov 2004.<\/li>\n<\/ol>\n
                                \n

                                2003<\/h3>\n<\/div>\n
                                  \n
                                1. Buchsbaum DJ,\u00a0Miller CR<\/b>, Mahasreshti P, Curiel DT.\u00a0 Cancer gene therapy.\u00a0 In:<\/i>\u00a0Oldham RK (ed), Principles of Cancer Biotherapy, 4th<\/sup>\u00a0Ed., Dordrecht: Kluwer, 2003. \u00a0Chapter 19: Pages 583-613.\u00a0\u00a0ISBN 1-4020-0706-X<\/a>.<\/li>\n<\/ol>\n

                                  2002<\/h3>\n
                                    \n
                                  1. Blanquicett C,\u00a0<\/sup>Gillespie GY, Nabors LB,\u00a0Miller CR<\/b>, Bharara S, Buchsbaum DJ, Diasio RB, Johnson MR. Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: Implications for a dual modality treatment using capecitabine and irradiation.\u00a0 Molecular Cancer Therapeutics 1(12):1139-1145 Oct 2002.\u00a0 PMID:\u00a012481438<\/a><\/li>\n
                                  2. Gustin A, Pederson L,\u00a0Miller R<\/b>, Chan C, Vickers SM.\u00a0 Application of molecular biology studies to gene therapy treatment strategies.\u00a0 World Journal of Surgery 26(7):854-860 Apr 2002.\u00a0 PMID:\u00a011960211<\/a><\/li>\n
                                  3. Miller CR<\/b>,\u00a0<\/b>Williams CR,\u00a0<\/b>Buchsbaum DJ, Gillespie GY.\u00a0 Intratumoral 5-fluorouracil produced by cytosine deaminase\/5-fluorocytosine gene therapy is effective for experimental human glioblastomas.\u00a0 Cancer Research 62(3):773-780 Feb 2002.\u00a0 PMID:\u00a011830532<\/a><\/li>\n
                                  4. Miller CR<\/b>, Gustin AN, Buchsbaum DJ, Vickers SM, Manne U, Grizzle WE, Cloud GA, Diasio RB, Johnson MR. Quantitation of cytosine deaminase mRNA by real-time reverse transcription polymerase chain reaction: A sensitive method for assessing 5-fluorocytosine toxicity\u00a0in vitro<\/i>.\u00a0 Analytical Biochemistry 301(2):189-199 Feb 2002.\u00a0 PMID:\u00a011814289<\/a><\/li>\n<\/ol>\n

                                    2000<\/h3>\n
                                      \n
                                    1. Kelly FJ,\u00a0Miller CR<\/b>, Buchsbaum DJ, Gomez-Navarro J, Barnes MN, Alvarez RD, Curiel DT.\u00a0 Selectivity of TAG-72 targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitro.\u00a0 Clinical Cancer Research 6(11):4323-4233 Nov 2000.\u00a0 PMID:\u00a011106250<\/a><\/li>\n<\/ol>\n

                                      1999<\/h3>\n
                                        \n
                                      1. Blackwell\u00a0<\/b>JL,\u00a0Miller CR<\/b>, Douglas JT, Li H, Reynolds PN, Carroll WR, Peters GE, Strong TV, Curiel DT.\u00a0 Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma.\u00a0 Archives of Otolaryngology, Head & Neck Surgery 125(8):856-863 Aug 1999.\u00a0 PMID:\u00a010448731<\/a><\/li>\n
                                      2. Miller CR<\/b>.\u00a0\u00a0Targeted adenovirus vectors<\/a>.\u00a0 Science & Medicine 6(5):18-19 Sep\/Oct 1999.<\/li>\n
                                      3. Douglas JT,\u00a0Miller CR<\/b>, Kim M, Dmitriev I, Mikheeva G, Krasnykh V, Curiel DT.\u00a0 A system for the propagation of adenoviral vectors with genetically modified receptor specificities.\u00a0 Nature Biotechnology 17(5):470-475 May 1999.\u00a0 PMID:\u00a010331807<\/a><\/li>\n<\/ol>\n

                                        1998<\/h3>\n
                                          \n
                                        1. Miller CR<\/b>, Buchsbaum DJ, Reynolds PN, Douglas JT, Gillespie GY, Mayo MS, Raben D, Curiel DT.\u00a0 Differential susceptibility of primary and established human glioma cells to adenovirus infection: Targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer.\u00a0 Cancer Research 58(24):5738-5748 Dec 1998.\u00a0 PMID:\u00a09865732<\/a><\/li>\n
                                        2. Reynolds PN,\u00a0Miller CR<\/b>, Goldman CK, Doukas J, Sosnowski BA, Rogers BE, Gomez-Navarro J, Pierce GF, Curiel DT, Douglas JT.\u00a0 Targeting adenoviral infection with basic fibroblast growth factor enhances gene delivery to vascular endothelial and smooth muscle cells.\u00a0 Tumor Targeting 3(3):156-164 Dec 1998.<\/li>\n
                                        3. Dmitriev I, Krasnykh V,\u00a0Miller CR<\/b>, Wang M, Kashentseva E, Mikheeva G, Belousova N, Curiel DT.\u00a0 An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. Journal of Virology 72(12):9706-9713 Dec 1998.\u00a0 PMID:\u00a09811704<\/a>\u00a0 PMCID:\u00a0PMC110480<\/a><\/li>\n
                                        4. Krasnykh V, Dmitriev I, Mikheeva G,\u00a0Miller CR<\/b>, Belousova N, Curiel\u00a0<\/b>DT.\u00a0\u00a0<\/b>Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob.\u00a0\u00a0<\/strong>Journal of Virology\u00a072(3):<\/strong>1844-1852 Mar 1998.\u00a0 PMID:\u00a09499035<\/a>\u00a0 PMCID:\u00a0PMC109474<\/a><\/li>\n<\/ol>\n

                                          1997<\/h3>\n
                                            \n
                                          1. Sevilla CL, Mahle NH, Eliezer N, Uzieblo A, O\u2019Hara SM, Nokubo M, Miller R<\/strong>, Rouzer CA, Marnett LJ. Development of monoclonal antibodies to the malondialdehyde-deoxyguanosine adduct, pyrimidopurinone.\u00a0 Chemical Research in Toxicology 10(2):172-180 Feb 1997.\u00a0 PMID: 9043428<\/a><\/li>\n<\/ol>\n

                                            1996<\/h3>\n
                                              \n
                                            1. Ebbinghaus SW, Vigneswaran N,\u00a0Miller CR<\/b>, Chee-Awai RA, Mayfield CA, Curiel DT, Miller DM.\u00a0 Efficient delivery of triplex forming oligonucleotides to tumor cells by adenovirus-polylysine complexes.\u00a0 Gene Therapy 3(4):287-297 Apr 1996.\u00a0 PMID:\u00a08732160<\/a><\/li>\n
                                            2. Miller R<\/b>, Curiel DT.\u00a0 Towards the use of replicative adenoviral vectors for cancer gene therapy.\u00a0 Gene Therapy 3(7):557-559 Jul 1996.\u00a0 PMID:\u00a08818641<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

                                              CRM NCBI Bibliography 2018 Koehler JW*, Miller AD*, Miller CR*, Porter B*, Aldape K, Beck J, Brat D, Cornax I, Corps K, Frank C, Giannini C, Horbinski C, Huse JT, O\u2019Sullivan MG, Rissi DR, Simpson RM, Woolard K, Shih JH, Mazcko C, Gilbert MR, LeBlanc AK. A revised diagnostic classification of canine glioma: Towards validation … Read more<\/a><\/p>\n","protected":false},"author":68816,"featured_media":0,"parent":92,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-94","page","type-page","status-publish","hentry","odd"],"acf":[],"yoast_head":"\nCRM Publications - C. Ryan Miller Lab<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.med.unc.edu\/pathology\/millerlab\/publications\/crm-publications\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CRM Publications - C. Ryan Miller Lab\" \/>\n<meta property=\"og:description\" content=\"CRM NCBI Bibliography 2018 Koehler JW*, Miller AD*, Miller CR*, Porter B*, Aldape K, Beck J, Brat D, Cornax I, Corps K, Frank C, Giannini C, Horbinski C, Huse JT, O\u2019Sullivan MG, Rissi DR, Simpson RM, Woolard K, Shih JH, Mazcko C, Gilbert MR, LeBlanc AK. A revised diagnostic classification of canine glioma: Towards validation … Read more\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.med.unc.edu\/pathology\/millerlab\/publications\/crm-publications\/\" \/>\n<meta property=\"og:site_name\" content=\"C. Ryan Miller Lab\" \/>\n<meta property=\"article:modified_time\" content=\"2018-12-27T16:06:03+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"25 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.med.unc.edu\/pathology\/millerlab\/publications\/crm-publications\/\",\"url\":\"https:\/\/www.med.unc.edu\/pathology\/millerlab\/publications\/crm-publications\/\",\"name\":\"CRM Publications - C. Ryan Miller Lab\",\"isPartOf\":{\"@id\":\"https:\/\/www.med.unc.edu\/pathology\/millerlab\/#website\"},\"datePublished\":\"2018-06-19T16:00:46+00:00\",\"dateModified\":\"2018-12-27T16:06:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.med.unc.edu\/pathology\/millerlab\/publications\/crm-publications\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.med.unc.edu\/pathology\/millerlab\/publications\/crm-publications\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.med.unc.edu\/pathology\/millerlab\/publications\/crm-publications\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.med.unc.edu\/pathology\/millerlab\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publications\",\"item\":\"https:\/\/www.med.unc.edu\/pathology\/millerlab\/publications\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"CRM Publications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.med.unc.edu\/pathology\/millerlab\/#website\",\"url\":\"https:\/\/www.med.unc.edu\/pathology\/millerlab\/\",\"name\":\"C. Ryan Miller Lab\",\"description\":\"Department of Pathology and Laboratory Medicine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.med.unc.edu\/pathology\/millerlab\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CRM Publications - C. Ryan Miller Lab","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/publications\/crm-publications\/","og_locale":"en_US","og_type":"article","og_title":"CRM Publications - C. Ryan Miller Lab","og_description":"CRM NCBI Bibliography 2018 Koehler JW*, Miller AD*, Miller CR*, Porter B*, Aldape K, Beck J, Brat D, Cornax I, Corps K, Frank C, Giannini C, Horbinski C, Huse JT, O\u2019Sullivan MG, Rissi DR, Simpson RM, Woolard K, Shih JH, Mazcko C, Gilbert MR, LeBlanc AK. A revised diagnostic classification of canine glioma: Towards validation … Read more","og_url":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/publications\/crm-publications\/","og_site_name":"C. Ryan Miller Lab","article_modified_time":"2018-12-27T16:06:03+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"25 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/publications\/crm-publications\/","url":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/publications\/crm-publications\/","name":"CRM Publications - C. Ryan Miller Lab","isPartOf":{"@id":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/#website"},"datePublished":"2018-06-19T16:00:46+00:00","dateModified":"2018-12-27T16:06:03+00:00","breadcrumb":{"@id":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/publications\/crm-publications\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.med.unc.edu\/pathology\/millerlab\/publications\/crm-publications\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/publications\/crm-publications\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/"},{"@type":"ListItem","position":2,"name":"Publications","item":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/publications\/"},{"@type":"ListItem","position":3,"name":"CRM Publications"}]},{"@type":"WebSite","@id":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/#website","url":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/","name":"C. Ryan Miller Lab","description":"Department of Pathology and Laboratory Medicine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links_to":[],"_links_to_target":[],"_links":{"self":[{"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/pages\/94","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/users\/68816"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/comments?post=94"}],"version-history":[{"count":0,"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/pages\/94\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/pages\/92"}],"wp:attachment":[{"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/media?parent=94"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}